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Olopatadine ophthalmic solution suppresses 
substance P release in the conjunctivitis models
Tadafumi Tamura
*
Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., 
Tokyo 100-8185, Japan
Background: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective 
histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. 
Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP 
release by anti-allergic ophthalmic solutions.
Objective: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) 
on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.
Methods: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively 
sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced 
conjunctivitis models.
Results: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced 
hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. 
Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.
Conclusion: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-
action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.
Key words: Olopatadine hydrochloride; Ophthalmic solution; Substance P; Allergic conjunctivitis; Rat
INTRODUCTION
Allergic diseases such as seasonal or perennial allergic 
conjunctivitis (AC) are closely related to a type I allergic reaction 
triggered by the allergen on the conjunctival mast cell. AC 
is caused by an allergen-induced inflammatory response, in 
which allergen-specific IgE antibodies bind to mast cells in 
the conjunctiva, triggering the release of chemical mediators, 
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including histamine and cytokines. Histamine binding to its 
receptors plays a central role in the induction of major allergic 
symptoms such as itching.
Choices for the treatment of AC are anti-allergy ophthalmic 
solution, steroid ophthalmic solution, and immunosuppressant 
ophthalmic solution; the first choice for the subject to the 
immediate phase of allergic inflammation may be anti-allergic 
ophthalmic solution.
Olopatadine hydrochloride ophthalmic solution (olopatadine) 
inhibits the binding of histamine to histamine H1 receptor, with 
superior histamine H1 receptor selectivity [1-3]. Olopatadine has 
also been shown to stabilize human conjunctival mast cells [1, 3, 4].
It has been reported that substance P (SP) levels are increased 
in tears of patients with AC compared with healthy individuals, 
suggesting that SP may contribute to the pathogenesis and 
severity of AC [5-7]. There are a variety of known itch-associated 
mediators in dermatitis, including histamine, neuropeptides (SP, 
calcitonin gene-related peptide, etc.), opioids, growth factors, 
cytokines, etc [8, 9]. Oral olopatadine was reported to mitigate 
cutaneous inflammation and the increased number of scratching 
episodes in a mouse model of chronic inflammatory dermatitis, 
accompanied by decreased cytokine and SP productions [10, 11]. 
However, little is known about the regulation of SP release by anti-
allergic ophthalmic drugs in AC.
The aim of this study is to supplement the known pharmacological 
profile of olopatadine with the commonly used anti-allergic 
ophthalmic solutions, levocabastine and tranilast in experimental 
rat conjunctivitis models. In addition, the release of SP was 
determined in the conjunctiva and tears using rat antigen-induced 
conjunctivitis models.
MATERIALS AND METHODS
Rats
Male 6-week-old Wistar rats were purchased from Charles 
River Japan (Japan). Animals were maintained at 19-25°C with 30-
70% of humidity on a 12 h light/dark cycle (light on at 7:00), and 
had free access to commercial pellets and water. Experiments 
were performed in accordance with recommendations of the 
institutional animal care and use committee of the Kyowa Hakko 
Kirin Co., Ltd. (Japan). 
Reagents
Ophthalmic solutions used in this study were olopatadine 
hydrochloride ophthalmic solutions (Patanol® ophthalmic solution 
0.1%, olopatadine 0.1%; Kyowa Hakko Kirin, Japan and Pataday
TM 
ophthalmic solution 0.2%, olopatadine 0.2%; Alcon Laboratories, 
USA), levocabastine ophthalmic solution (Livostin® Eye Drops 
0.025%, levocabastine; Janssen Pharmaceutical, Japan), and 
tranilast ophthalmic solution (Rizaben® Eye Drops 0.5%, tranilast; 
Kissei Pharmaceutical, Japan). Reagents used in this study were 
histamine dihydrochloride (Histamine; Sigma-Aldrich, USA), 
albumin (Ovalbumin, OVA; Sigma-Aldrich, USA) and Evans blue 
(Sigma-Aldrich, USA).
Histamine-induced conjunctival vascular 
hyperpermeability in rats
To compare the anti-histamine efficacy, conjunctival vascular 
hyperpermeability was induced by histamine in rats. Rats were 
injected with 30 μL of histamine (0.1 mg/mL) by the upper 
subconjunctiva under isoflurane anesthesia immediately after 
the intravenous injection of 1.5 w/v% Evans blue solution. Thirty 
min later, the animals were sacrificed and the bluing eye (eyelids 
and eyeballs) was removed. Dye which had leaked into the tissue 
was extracted with formamide at 45°C and its absorbance at 625 
nm was determined with a spectrophotometer (THERMOmax
TM; 
Molecular Devices, USA). Values     were analyzed as per weight of 
each organization. Ophthalmic solutions or saline were applied to 
the eyes (10 μL per eye) 30 min prior to the challenge of histamine. 
As negative control, rats were injected with 30 μL of saline by the 
upper subconjunctiva and were injected with 1.5 w/v% Evans blue 
solution.
Antigen-induced conjunctival vascular 
hyperpermeability in passively sensitized rats
Conjunctival vascular hyperpermeability were induced by an 
experimental AC in passively sensitized rats. Anti-OVA antiserum 
containing IgE antibody was prepared by the method of Stotland 
and Share [12] using male rats. Rats were passively sensitized 
with 30 μL of anti-OVA antiserum by the upper subconjunctival 
injection under isoflurane anesthesia. Forty-eight h after the 
sensitization, the animals were subjected to challenge by an 
intravenous injection of OVA (2 mg/mL) solution containing 1.5 w/
v% Evans blue. Thirty min later, the animals were sacrificed and 
the bluing eye (eyelids and eyeballs) was removed. Dye which had 
leaked into the tissue was determined by the method described apallergy.org
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above. Ophthalmic solutions or saline were applied to the eyes (10 
μL per eye) 30 min prior to the challenge of antigen. As negative 
control, sensitized rats were injected with 1.5 w/v% Evans blue.
The onset and duration of action of olopatadine on the 
conjunctival vascular hyperpermeability in antigen-
induced conjunctival vascular hyperpermeability
Conjunctival vascular hyperpermeability were induced by an 
experimental AC in passively sensitized rats. Ophthalmic solutions 
or saline were applied to the eyes (10 μL per eye) 24 h, 6 h prior to 
the challenge of antigen, or 5 min after the challenge of antigen. 
As negative control, sensitized rats were injected with 1.5 w/v% 
Evans blue.
Measurement of SP in conjunctiva
We determined the levels of SP in the conjunctiva using rat 
antigen-induced conjunctivitis models. Sensitized rats were 
subjected to challenge by an intravenous injection of OVA 
solution. Ophthalmic solutions were instilled at 30 min before 
antigen challenge and immediately after antigen challenge into 
the bilateral eye with 10 μL/site. Thirty min later, the animals were 
sacrificed and the conjunctivas were removed. The removed 
tissue was homogenized in phosphate buffered saline containing 
the protease inhibitor. After centrifugation, the supernatant was 
collected and stored at −35°C. SP levels were determined using 
commercial SP assay kit (Cayman Chemical, USA) according to 
the provided protocol. The absorbance was measured using a 
microplate spectrophotometer. The determined values were 
analyzed as values per total protein. The percentage of SP 
release calculated [13]: SP release (%) = [(Average of SP level of 
the conjunctiva in the pre group) − (Average of SP level of the 
conjunctiva in the control group or the drug treated group)] / 
(Average of SP level of the conjunctiva in the pre group) × 100.
Measurement of SP in tears
Moreover, we determined the levels of SP in tears using rat 
antigen-induced conjunctivitis models. Another sensitized rat 
was subjected to challenge by an intravenous injection of OVA 
solution. Thirty min later, 50 µL saline was applied to both eyes. 
This procedure was repeated 3 times and a 200 µL sample was 
carefully collected from both eyes. After centrifugation, the 
supernatant was collected and SP levels were determined using 
commercial SP assay kit according to the provided protocol. The 
determined values were analyzed as values per total protein.
Statistical analysis
Data were presented as means ± SE. The Aspin-Welch test 
or Student’s t-test following the F-test was used for analysis 
of differences between two groups. Values of p < 0.05 were 
considered statistically significant. 
RESULTS
Histamine-induced conjunctival vascular 
hyperpermeability in rats
The amount of dye leaked by the injection of histamine into 
the upper subconjunctiva was significantly increased compared 
to saline-injected animals (p < 0.0001) (Fig. 1A). Olopatadine 0.1% 
and olopatadine 0.2% significantly suppressed the increased 
conjunctival dye leaked (p < 0.0001, p < 0.0001). Levocabastine 
also significantly inhibited the increased conjunctival dye leaked 
by histamine (p = 0.0007). Tranilast did not significantly inhibit. 
These inhibitory effects of olopatadine were more potent than for 
other tested anti-allergic ophthalmic solutions.
Antigen-induced conjunctival vascular 
hyperpermeability in passively sensitized rats
To elucidate the ocular anti-allergic efficacy of olopatadine and 
other anti-allergic ophthalmic solutions, we investigated in rat 
antigen-induced conjunctivitis models (Fig. 1B). The amount of 
dye leaked by the intravenous injection of OVA was significantly 
increased compared to saline-injected animals (p < 0.0001). When 
olopatadine 0.1% and 0.2% were instilled into rats eyes 30 min 
before antigen challenge, the increased conjunctival dye leaked 
were significantly suppressed at both concentrations (p < 0.0001, 
p < 0.0001). Levocabastine and tranilast also significantly inhibited 
the increased conjunctival dye leaked by antigen (p = 0.0001, p = 
0.0061). These inhibitory effects of olopatadine were more potent 
than for other tested anti-allergic ophthalmic solutions.
The onset and duration of action of olopatadine 
on antigen-induced conjunctival vascular 
hyperpermeability in passively sensitized rats
Next, the onset and duration of action of olopatadine on the 
conjunctival vascular hyperpermeability were investigated in rat 
AC (Fig. 2). Ophthalmic solutions were applied topically onto eyes 
24 h or 6 h prior to the challenge of antigen, or 5 min after the 
challenge of antigen. Pre-treatment 6 h with olopatadine 0.1% apallergy.org
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and 0.2% significantly inhibited the increased conjunctival dye 
leaked by 75.7% and 89.2% inhibition (p < 0.0001, p < 0.0001). 
Pre-treatment 24 h with olopatadine 0.1% and 0.2% significantly 
inhibited the increased conjunctival dye leaked by antigen by 
71.6% and 80.4% inhibition (p = 0.0001, p = 0.0003). Moreover, 
when ophthalmic solutions were applied to the eyes 5 min 
after the challenge of antigen, olopatadine 0.1% and 0.2% also   
significantly inhibited the increased conjunctival dye leaked by 
59.7% and 77.8% (p = 0.0006, p = 0.0002).
Effect of olopatadine on SP release from the 
conjunctiva
Fig. 3A shows the effect of olopatadine and other anti-allergic 
ophthalmic solutions on SP release from the rat conjunctiva. SP 
contents in the conjunctiva was increased significantly by the OVA 
sensitization compared with normal rats (p = 0.0088), while it 
was decreased significantly after the OVA challenge (p = 0.0044), 
and the percentage of SP release by the OVA challenge was 33.1% 
(Fig. 3B). Olopatadine 0.1% and 0.2% significantly inhibited the 
decreased conjunctival SP contents (p = 0.0324, p = 0.0040), and 
their percentages of SP release were 13.7% and 8.2%. Therefore, 
olopatadine inhibited SP release from the conjunctiva. On the 
other hand, other anti-allergic ophthalmic solutions did not inhibit 
the decrease in the levels of SP.
Effect of olopatadine on the levels of SP in tears
To elucidate the SP release of olopatadine and other anti-allergic 
ophthalmic solutions, we determined the levels of SP in tears using 
rat antigen-induced conjunctivitis model (Fig. 4). The levels of SP in 
tears were significantly increased by the OVA challenge compared 
with normal rats. Olopatadine 0.1% and 0.2% significantly inhibited 
the increase in the levels of SP in tears (p = 0.0054, p = 0.0005). 
The levels of SP in tears after application of olopatadine 0.2% was 
significantly less than those of application of olopatadine 0.1% (p 
= 0.0225). Tranilast also significantly inhibited the increase in the 
levels of SP (p = 0.0392). On the other hand, levocabastine did not 
inhibit the increase in the levels of SP.
Fig. 1. Effects of olopatadine ophthalmic solution 0.1% and 0.2% compared other anti-allergic ophthalmic solutions on histamine (A) or ovalbumin (B)-
induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine 0.1%, olopatadine 0.2%, levocabastine 0.025%, and tranilast 
0.5% were applied topically onto the eye 30 min before the challenge of antigen and histamine with Evans blue dye. Each column and vertical bar 
represents the mean ± SE of 8-11 rats. 
**p < 0.01, 
***p < 0.001: significantly different from the control group (Student’s t-test). 
###p < 0.001: significantly 
different from the control group (Aspin Welch test). 
Fig. 2. Effects of olopatadine ophthalmic solution 0.1% and 0.2% on 
ovalbumin-induced conjunctival vascular hyperpermeability in passively 
sensitized rats. Olopatadine ophthalmic solution 0.1% (olopatadine 
0.1%), olopatadine ophthalmic solution 0.2% (olopatadine 0.2%) were 
applied topically onto the eyes 24 h, 6 h prior to the challenge of antigen, 
and 5 min after the challenge of antigen. Each column and vertical bar 
represents the mean ± SE of 4-7 rats. 
***p < 0.001: significantly different 
from the control group (Student’s t-test). 
###p < 0.001: significantly 
different from the control group (Aspin Welch test).
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DISCUSSION
In this study, a rat model of conjunctivitis was used to examine 
the ocular anti-histamine and anti-allergic efficacies of olopatadine 
ophthalmic solution compared with other anti-allergic ophthalmic 
solutions. The present study also demonstrated that the SP levels 
were decreased in the conjunctiva and increased in tears in rat 
antigen-induced conjunctivitis models. This is in agreement with 
the clinical studies [5, 14], which showed that the level of SP in 
tears was abundant at the onset of allergy symptoms.
The different mechanisms of action of the anti-allergy ophthalmic 
solutions possibly account for the observed differences in efficacy. 
Olopatadine ophthalmic solution is a highly effective dual-action 
drug with selective histamine H1 receptor antagonistic action and 
human conjunctival mast cell stabilization action. Levocabastine is 
a histamine H1 receptor antagonist. Tranilast is characterized as a 
mediator release inhibitor. At first, to compare the anti-histamine 
efficacy, conjunctival vascular hyperpermeability was induced 
by subconjunctival injection of histamine. It has demonstrated 
that olopatadine ophthalmic solution inhibits binding of 
histamine to H1 receptors, with superior H1 receptor selectivity 
compared with other anti-allergic ophthalmic solutions [1-3]. 
In this study, olopatadine 0.1% and 0.2% significantly inhibited 
the increased conjunctival dye leaked in the histamine-induced 
hyperpermeability model. These anti-histamine effects were more 
potent than for other tested anti-allergic ophthalmic solutions. In 
contrast, tranilast did not significantly inhibit.
Next, to compare the anti-allergic efficacy, antigen-induced 
conjunctivitis model was induced by intravenous injection of OVA 
in rats passively sensitized with anti-OVA antiserum. The inhibitory 
effects of olopatadine ophthalmic solutions in rat antigen-induced 
conjunctivitis models also were more potent than for other tested 
Fig. 3. Effects of olopatadine ophthalmic solution compared other anti-allergic ophthalmic solution on substance P (SP) contents (A) and SP release 
(B) in conjunctiva induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions 
were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye with 10 μL/site. Each column and verti-
cal bar of SP contents (A) represents the mean ± SE of 7-9 rats. 
*p < 0.05, 
**p < 0.01: significantly different from the control group (Student’s t-test). 
††p < 
0.01: significantly different from the pre group (Student’s t-test).
Fig. 4. Effects of olopatadine ophthalmic solution and other anti-allergic 
ophthalmic solutions on substance P (SP) contents in tears induced by 
ovalbumin in passively sensitized rats. SP contents were measured 30 min 
after antigen challenge. Ophthalmic solutions were instilled at 30 min 
before antigen challenge and immediately after antigen challenge into 
the bilateral eye at 10 μL/site. Each column and vertical bar represents 
the mean ± SE of 5-7 rats. 
*p < 0.05, 
**p < 0.01, 
***p < 0.001: significantly 
different from the control group (Student’s t-test). 
†p < 0.05: significantly 
different  from the olopatadine 0.1% group (Student’s t-test).
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anti-allergic ophthalmic solutions. In this model, tranilast also 
significantly inhibit it.
Histamine and various cytokines are released from conjunctival 
epithelial cells and mast cells by antigen-antibody reaction [1-3]. 
Olopatadine ophthalmic solution has been shown to suppress 
the histamine release in a concentration-dependent manner from 
human conjunctival mast cells [4, 15]. These effects of olopatadine 
0.1% and 0.2% are continued and faster than other tested anti-
allergic ophthalmic solutions on the conjunctival vascular 
permeability in antigen-induced conjunctivitis models.
So, the levels of histamine and SP in the conjunctiva and tears 
were actually determined in rat antigen-induced conjunctivitis 
models. Histamine levels in the conjunctiva were decreased by 
antigen-antibody reaction, but histamine levels in tears were not 
influenced (data not shown). SP levels in the conjunctiva were 
decreased and SP levels in tears were increased, suggesting that 
SP was released from the conjunctiva due to antigen-antibody 
reaction. Although SP induced the conjunctivitis in guinea pig, 
histamine level in the conjunctiva had no influence [4]. SP may 
be involved in the conjunctivitis not through histamine. In the 
dermatitis, SP is released from sensory nerve endings and cause 
histamine release from mast cells [16]. The visual analogue scale 
(VAS) score, which evaluated the subjective symptoms of ocular 
allergy, at the onset of symptoms correlated with tears histamine 
levels. It have been reported that olopatadine ameliorated the VAS 
score and decreased the SP levels in tears at the onset of ocular 
symptoms [14]. In the present study shows that SP are released 
in tears and may play a role in rat antigen-induced conjunctivitis 
models. Olopatadine ophthalmic solutions significantly inhibited 
the release of SP from the conjunctiva and the amount of SP 
in tears. On the other hand, tranilast significantly inhibited the 
amount of SP in tears, and levocabastine failed to inhibit the 
release of SP from the conjunctiva and the amount of SP in tears. 
The VAS score at the onset of symptoms correlated with histamine 
levels in tears [14]. Although SP also plays an important role in 
inflammation caused by an increase in vascular permeability, 
ocular allergy symptoms may be mainly induced by vasoactive 
amines in rat antigen-induced conjunctivitis models. Therefore, 
it is suggested that anti-allergic ophthalmic solutions suppressed 
the conjunctival vascular hyperpermeability in rat antigen-induced 
conjunctivitis models.
The effects of olopatadine 0.2% to the conjunctival vascular 
hyperpermeability were showing a strong tendency compared 
with those of olopatadine 0.1%, especially, the inhibitory of 
SP release to tears was significantly strong. SP is known itch-
associated mediators in dermatitis, however, little is known about 
the association in AC. It has been reported that oral olopatadine 
attenuates the amount of scratching behavior and suppress the 
increased SP levels in the skin lesions in mice chronic inflammatory 
dermatitis [10, 11]. It is suggested that chemical mediators 
including histamine and SP in tears also involved in itching and 
ocular symptoms. In the clinical study, neuropeptides are up-
regulated and their release in nasal fluids has been demonstrated 
after allergen exposure [17]. The symptoms of allergic rhinitis are 
not only with nasal symptoms but also with severe ocular itching. 
Ocular itching adversely affect the quality of life of patients with 
allergic rhinitis and allergic rhinoconjunctivitis.
These results indicate that olopatadine ophthalmic solution 
appears to exert additional SP release inhibition besides its well 
established dual-action such as selective histamine H1 receptor 
antagonistic action and human conjunctival mast cell stabilization 
action. Olopatadine ophthalmic solution may be useful as the first 
choice for the treatment of AC.
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